Background: Group B Streptococcus (GBS) is a commensal vaginal bacterium that can lead to adverse maternal and neonatal outcomes. In low or middle-income countries, few data are available regarding the immune-inflammatory response in GBS-colonized pregnant mothers and its association with the risk of neonatal invasive disease. In this investigation, we implement a prospective study on a cohort of mother–newborn dyads in Morocco to assess the cytokine profile in GBS-colonized-mothers whose newborns have invasive GBS disease. Methods: Pregnant women between 35 and 40 weeks of gestation were screened for vaginal colonization by GBS and followed up until delivery. A panel of inflammatory cytokines was quantified by Luminex multiplex assays and by ELISA in maternal and cord blood, as well as in supernatants after stimulation of pathogen recognition receptors. GBS-colonized-mothers were clustered according to clinical and inflammation markers and to their newborn's infection status. Results: GBS-colonized-mothers whose newborns developed invasive GBS disease exhibited significantly lower IL-1β, IL-4, and IL-17A production compared with GBS-colonized-mothers with healthy newborns. Similar results were obtained following ex vivo stimulation of peripheral blood cells by TLR4 and TLR1/2 ligands. The level of circulating maternal IL-17A had a higher significant predictive value for GBS transmission leading to invasive neonatal disease. Conclusions: This study shows that GBS-colonized-mothers may exhibit a greater cytokine inflammatory response compared with noncolonized-mothers. Regarding mother–newborn dyads, maternal IL-17A, a key mediator of antibacterial defense, emerges as a significant prognostic biomarker for assessing the risk of GBS transmission and the development of neonatal GBS invasive disease.
Group B streptococcus (GBS) is a commensal bacterium that can cause severe infection in neonates. Vaginal colonization with GBS is a risk factor for mother
The transmission of pathogenic Gram-negative bacteria such as Escherichia coli and Klebsiella pneumoniae from mother to child during pregnancy contributes significantly to neonatal morbidity and mortality, particularly in low and middle-income countries. Identifying maternal risk factors associated with vertical transmission is crucial. This prospective study aimed to investigate the maternal cytokine profile and anti-LPS-specific antibodies in pregnant mothers with positive cultures for E. coli and K. pneumoniae, exploring their potential association with neonatal invasive disease. This prospective study examined groups of pregnant women with a positive culture for E. coli or K. pneumoniae, who had or had not given birth to newborns with invasive diseases. A group of age-matched mothers negative for E coli and K. pneumoniae was used as a control. A panel of circulating inflammatory cytokines was measured in mother-infant dyads using Luminex multiplex assays or ELISA in maternal and cord blood, as well as in the supernatants of blood leucocytes stimulated with TLR4 and TLR1/2 ligands. The serum levels of specific IgG anti-LPS E. coli and anti-LPS K. pneumoniae were quantified using ELISA. Mothers with a positive culture for E. coli and K. pneumoniae and their newborns exhibited elevated plasma levels of IL-6, IL-8, and TNF-α compared to healthy mothers and their newborns. Similar results were observed for IL-6 and TNF-α when blood leucocytes were stimulated by TLR4 and TLR1/2 ligands. Mothers who gave birth to newborns with severe infectious diseases had higher IL-6 levels and lower specific IgG anti-LPS E. coli or anti-LPS K. pneumoniae levels compared to those with healthy newborns. Receiver operating characteristic (ROC) analysis demonstrated a strong association between maternal IL-6 and specific IgG levels and perinatal bacterial transmission. Pregnant women with positive cultures for E. coli or K. pneumoniae, as well as higher plasma levels of IL-6 and lower levels of specific anti-bacterial IgG, are at increased risk of perinatal bacterial transmission. This data could help improve the monitoring of mother-child dyads and optimize prenatal care. Clinical trial number: not applicable.
Introduction: this study aimed to investigate the prevalence and management of food allergies (FA) and drug allergies (DA) in Morocco. Sparse and conflicting epidemiological data exist on the exact prevalence of allergies in the country. The rise in allergies can be attributed to various factors. Methods: the study analyzed data from patients with suspected FA and DA who sought medical attention. Statistical tests were used to analyze the data, percentages were computed for qualitative variables, and for quantitative variables, medians or means accompanied by standard deviations (SD) were calculated. The Chi-square test was employed to assess categorical variables. A p -value < 0.05 was considered statistically significant. Results: Cow's milk was the most reported food allergen (58.2%), followed by egg and nuts (23.4% and 12.1%, respectively). The most affected age group was children under 5 years. Antibiotics were the leading cause of reported drug allergies (44.8%), particularly Beta-lactams. Immediate reactions were commonly associated with antibiotics and nonsteroidal anti-inflammatory drugs (NSAIDs). Symptoms of FA included acute urticaria, vomiting, anaphylactic shock, and facial edema. Urticaria was the most frequent symptom of DA. Antihistamines and corticosteroids were the main treatments used for both FA and DA. Conclusion: the prevalence of FA and DA in Morocco remains uncertain due to limited data. There is a need for centralized data collection and awareness among clinicians and the general population regarding allergies. The study highlights the importance of proper diagnosis and management of allergies to ensure patient safety. The findings emphasize the necessity of establishing a mandatory center for allergy care in Morocco to improve the understanding and management of allergic conditions.